Follow-up of the efficacy of topical CG428 for chemotherapy-induced nail damage in breast cancer patients undergoing adjuvant chemotherapy.

Follow-up of the efficacy of topical CG428 for chemotherapy-induced nail damage in breast cancer patients undergoing adjuvant chemotherapy. - Follow-up of the efficacy of CG428 on nail disorders in breast cancer patients undergoing chemotherapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000048583

Enrollment

Registered

2022-08-12

Start date

2022-08-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Use of topical formulation CG428 CG428 is applied to all nails on both hands and feet twice daily, morning and evening, using a brush to apply CG428 from the nail to the skin around the nail. Using C

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Patients with Stage I-III primary breast cancer diagnosed histologically at Nagasaki Harbor Medical Center between July 1, 2022 and June 30, 2024. 2. Patients with primary breast cancer who are planned to receive an anthracycline and a taxane, or a taxane and a platinum-based therapy, or a taxane-based therapy as preoperative or postoperative adjuvant therapy. (Use of trastuzumab or pertuzumab is not restricted. 3. Patients who have been fully informed about their participation in the study and who have given their free and voluntary consent based on their full understanding of the study.

Exclusion criteria

Exclusion criteria: 1. Patients undergoing chemotherapy treatment for other diseases 2. Patients with pre-treatment nail symptoms 3. Patients receiving any kind of treatment for nail symptoms 4. Patients with a history of hypersensitivity to ingredients of topical agents (e.g. ethanol), cosmetics, hair growth products, etc. 5. Other patients deemed inappropriate as research subjects by the investigators

Design outcomes

Primary

Measure	Time frame
Time to cure of nail symptoms(Before the start of chemotherapy, after completion of 1 regimen, after completion of 2 regimens, and 3, 6, 9, and 12 months after completion of chemotherapy)	—

Secondary

Measure	Time frame
Assessment of morbidity of nail symptoms, and quality of life related to nail symptoms(Before the start of chemotherapy, after completion of 1 regimen, after completion of 2 regimens, and 3, 6, 9, and 12 months after completion of chemotherapy)	—

Countries

Japan

Contacts

Public ContactToshinobu Ina

Nagasaki Harbor Medical Center Innovation and Translational Research Center

kenkyu-ml@ncho.jp095-822-3251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026